New pill shows promise for severe baldness, but trial cut short
NCT ID NCT05496426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called KL130008 in 114 adults with severe alopecia areata, a condition causing major hair loss. The goal was to see if the drug could safely regrow hair, measured by how many people achieved 80% or more scalp coverage. However, the trial was terminated early, so we have less information than planned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KL130008 capsule
- What this could lead to
- If successful, this could point toward a new treatment option for people with severe alopecia areata, potentially regrowing significant hair.
- What could go wrong
- This trial was terminated early, so results may be incomplete. It's a Phase 2 study, meaning it's still early and may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangzhou, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill help teens regrow hair lost to alopecia?
- Can allergy and glaucoma drugs regrow hair when delivered by microneedling?
- Can a daily pill bring back hair in severe alopecia?
- Can Real-World data unlock better skin disease care?
- Can a daily pill regrow hair in alopecia areata? a trial seeks answers
- Blood test may reveal hidden clues to hair loss severity